Trial record 1 of 6 for:
mgd006
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (VOYAGE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02152956 |
|
Recruitment Status :
Active, not recruiting
First Posted : June 2, 2014
Last Update Posted : March 21, 2022
|
Sponsor:
MacroGenics
Information provided by (Responsible Party):
MacroGenics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Open-label, multi-dose, single-arm, multi-center, Phase 1/2 study conducted in three segments: the Single Patient Dose Escalation Segment (complete), followed by the Multi-Patient Dose Escalation Segment (complete) and the Maximum Tolerated Dose and Schedule (MTDS) Expansion Cohort Segment (ongoing). Having characterized safety and determined the maximum tolerated dose and schedule, the primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve CR or CRh. Starting with Cycle 2, patients who are benefiting from flotetuzumab may receive up to a maximum of 8 cycles of treatment.
Patients will receive daily increasing doses of flotetuzumab for the first week of Cycle 1 (Lead-In Dosing) followed by 3 weeks of continuous intravenous infusion at a specifiedthe assigned dose. Subsequent cycles are each 4 weeks of continuous infusion at the assigned dose. Dosing may continue for up to 8 cycles. Follow up visits may continue for 6 months after treatment is discontinued.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| AML | Biological: Flotetuzumab dose escalation Biological: Flotetuzumab dose expansion Drug: Ruxolitinib | Phase 1 Phase 2 |
Expanded Access : An investigational treatment associated with this study is available outside the clinical trial. More info ...
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 330 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS) |
| Actual Study Start Date : | June 9, 2014 |
| Estimated Primary Completion Date : | July 2023 |
| Estimated Study Completion Date : | December 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Familial acute myeloid leukemia with mutated CEBPA
Cytogenetically normal acute myeloid leukemia
Core binding factor acute myeloid leukemia
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Flotetuzumab dose escalation:
Participants will be assigned sequentially to escalating doses of flotetuzumab, up to the maximum tolerated dose (MTD).
|
Biological: Flotetuzumab dose escalation
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
Other Name: MGD006 |
|
Experimental: Flotetuzumab dose expansion
Participants will receive flotetuzumab at the recommended phase 2 dose (RP2D) and schedule identified during dose escalation.
|
Biological: Flotetuzumab dose expansion
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
Other Name: MGD006 |
|
Experimental: Flotetuzumab and ruxolitinib
Participants will receive flotetuzumab at the recommended phase 2 dose (RP2D) and schedule identified during dose escalation in combination with one of two escalating doses of ruxolitinib.
|
Biological: Flotetuzumab dose expansion
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
Other Name: MGD006 Drug: Ruxolitinib Ruxolitinib will be administered at the assigned dose.
Other Name: Jakafi |
Primary Outcome Measures :
- Efficacy based on CR or CRh rate [ Time Frame: up to 14 months ]Proportion of patients achieving a best response of CR (morphologic CR [mCR], cytogenetic CR [CRc], molecular CR [CRm], or CRh per Interworking Group AML response criteria.
Secondary Outcome Measures :
- Overall complete response rate [ Time Frame: 14 months ]Rate of CR + CRh + CRi (CR with incomplete blood cell recovery [CR with incomplete neutrophil {CRn}or platelet recovery {CRp}]) + MLFS (morphologic leukemia-free state)
- CR rate [ Time Frame: 14 months ]Proportion of patients achieving a best response of CR (morphologic CR [mCR], cytogenetic CR [CRc], or molecular CR [CRm] per Interworking Group AML response criteria.
- CRh rate [ Time Frame: 14 months ]Proportion of patients achieving a best response of CRh per Interworking Group AML response criteria.
- Duration of response of patients with CR or CRh [ Time Frame: Up to 2 years ]Time of initial documentation of response to the time of disease relapse or death due to any cause, whichever occurs first.
- Post-baseline transfusion independence rate [ Time Frame: 56 days ]The number of patients who were transfusion-dependent at baseline and did not receive transfusions during any consecutive 56-day period will be calculated. The number of patients who are transfusion independent at baseline and remain independent during any 56-day post-baseline period will also be calculated.
- Overall survival [ Time Frame: Up to 2 years ]Time from first dose to death from any cause
- HSCT rate [ Time Frame: 8 months ]Rate of successful hematopoietic stem cell transplantation (HSCT) after the start flotetuzumab treatment and before subsequent therapy.
- Incidence rate of hospitalization for patients in the Expansion Cohort [ Time Frame: 8 months ]Incidence rate of hospitalization will be calculated
- Duration of hospitalization for patients in the Expansion Cohort [ Time Frame: 8 months ]Duration of hospitalization will be characterized
- Event-free survival [ Time Frame: Up to 2 years ]Time from the first dose of study drug until date of evidence of progression, relapse, or death from any cause, whichever occurs first.
- Time to response [ Time Frame: 14 months ]Time from first dose of study drug to first CR, CRh, CRi, or MLFS
- Mortality rate [ Time Frame: Up to 180 days ]rate of death from any cause within 30, 60, 90, or 180 days of first dose of study drug
- 6-month survival rate [ Time Frame: 6 months ]Probability of survival at 6 months from first dose of study drug
- One-year survival rate [ Time Frame: 1 year ]Probability of survival at 1 year from first dose of study drug
- Number of patients with infusion related reaction (IRR)/cytokine release syndrome (CRS) management [ Time Frame: During study drug administration (up to 8 months) ]Determine safety and efficacy of tocilizumab in the treatment of IRR/CRS as measured by incidence of IRR/CRS
- Occurrence of dose limiting toxicity [ Time Frame: Cycle 1 of a 28 day cycle. ]Maximum Tolerated Dose/Schedule: the MTDS is defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is < 33% during the first cycle of MGD006 treatment.
- Occurrence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 9 months ]Cycle 1 through end of treatment
- Serum concentration of flotetuzumab [ Time Frame: Study day 1, then every 28 days and 28 days after the last dose (up to 8 months) ]Measure the pharmacokinetics (PK) of flotetuzumab
- ADA [ Time Frame: Study Day 1, then every 28 days through 28-days after the last dose (up to 8 months) ]Occurrence of anti-drug antibody
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Confirmed diagnosis of primary or secondary AML [any subtype except acute promyelocytic leukemia (APL)] according to World Health Organization (WHO) classification
-
Patients with AML must meet one of the following criteria, a or b:
-
Primary Induction Failure (PIF) AML, defined as disease refractory to either, i or ii:
- i. An intensive induction attempt, per institution. Induction attempts include high-dose and/or standard-dose cytarabine ± an anthracyclines/anthracenedione ± an anti-metabolite, with or without growth factor or targeted therapy containing regimens. Examples include but are not limited to: 1 cycle of high dose cytarabine (HiDAC) containing regimen, 1 cycle of liposomal cytarabine and daunorubicin, 2 cycles of standard dose cytarabine containing regimen
- ii. For adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; PIF is defined as AML refractory to one of the following less intensive regimens: i ≥ 2 but ≤ 4 cycles of Bcl-2 inhibitors in combination with azacitidine, decitabine, or low dose cytarabine, or ii ≥ 2 but ≤ 4 cycles of gemtuzumab ozogamicin monotherapy
- Early relapse (ER) AML, defined as AML in first relapse with initial CR1 duration < 6 months
-
- Limit of 3 prior lines of therapy (excluding focal radiation therapy for palliative purposes): up to 2 induction (induction, re-induction) or 1 induction plus/minus 1 consolidation attempt, followed by a maximum of 1 salvage/re-induction attempt.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- Life expectancy of at least 4 weeks
- Peripheral blast count </= 20,000/mm3 at the time of first dose
- Acceptable laboratory parameters and adequate organ reserve
Exclusion Criteria:
- History of allogeneic stem cell transplantation
- Prior treatment with an anti-CD123-directed agent
- Need for concurrent other cytoreductive chemotherapy
- Any active untreated autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid clinically and with stable supplementation)
- Second primary malignancy that requires active therapy. Adjuvant hormonal therapy is allowed.
- Antitumor therapy or investigational agent within 14 days or 5 half-lives of Cycle 1 Day 1.
- Requirement, at the time of study entry, for concurrent steroids > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, otic preparations, nasal spray or ophthalmic solution
- Use of immunosuppressant medications in the 2 weeks of Cycle 1 Day 1
- Use of granulocyte colony stimulating or granulocyte-macrophage colony stimulating factor in the 2 weeks of Cycle 1 Day 1
- Known central nervous system (CNS) leukemia
- Active uncontrolled infection (including, but not limited to viral, bacterial, fungal, or mycobacterial infection),
- Known human immunodeficiency virus infection, unless all of the following criteria are met: CD4+ count ≥ 350 cells/μL, undetectable viral load, and receiving highly active antiretroviral therapy.
- Known, active, history of or current acute or chronic hepatitis B or C virus (HBV) infection (as evidenced by detectable HBV surface antigen and HBV DNA ≥ 500 IU/mL),
- History of hepatitis C virus (HCV) infection, unless the infection has been treated and cured,
- Active SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study entry, testing for ongoing infection should follow local clinical practice guidelines/standards. Participants with a positive test result for ongoing SARS-CoV-2 infection, known asymptomatic infection, or suspected infection are excluded unless or until asymptomatic and with subsequent negative SARS-CoV-2 laboratory test.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02152956
Locations
Show 43 study locations
Sponsors and Collaborators
MacroGenics
Investigators
| Study Director: | Ashley L. Ward, MD | MacroGenics |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | MacroGenics |
| ClinicalTrials.gov Identifier: | NCT02152956 |
| Other Study ID Numbers: |
CP-MGD006-01 |
| First Posted: | June 2, 2014 Key Record Dates |
| Last Update Posted: | March 21, 2022 |
| Last Verified: | March 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by MacroGenics:
|
AML leukemia myelogenous myeloid refractory |